Figures computed from official regulatory filings — .
Analysttarget 3.67 USD (-1%) · consensus 2.8/5 · 0 buy · 4 hold · 1 sell
Ownershipinsiders 3.35% · institutions 103.51% · short 9.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Fulcrum Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
27 buys69 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| TANG KEVIN Ctrack record | Buy | $415.3K | conv 53Unusual size |
| SEC |
| TANG KEVIN Ctrack record | Buy | $179.3K | conv 33 | SEC |
| TANG KEVIN Ctrack record | Buy | $382.3K | conv 52Unusual size | SEC |
| TANG KEVIN Ctrack record | Buy | $271.9K | conv 29 | SEC |
| TANG KEVIN Ctrack record | Buy | $191K | conv 29 | SEC |
| TANG KEVIN Ctrack record | Buy | $45.9K | conv 29 | SEC |
| GERAGHTY JAMES Atrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dorton Katina | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Haviland Kate | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Banks Sonja | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hill Colin | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ezekowitz Alan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gould Robert J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| King Rachel K. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ezekowitz Alan | Sell | $65.6K | SEC |
| Lehrer-Graiwer Joshua | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Musso Alan A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gould Robert J | Sell | $160.8K | SEC |
| Tourangeau Greg | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sapir Alex | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gould Robert J | Sell | $163.1K | SEC |
| Oltmans Curtis Gale | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Oltmans Curtis Gale | Sell | $44.6K | SEC |
| RA Capital Biotech Fund LPtrack record | Sell | $1.4M | SEC |
| RA Capital Biotech Fund LPtrack record | Sell | $18.4M | Unusual size | SEC |